256 related articles for article (PubMed ID: 15792995)
1. Inhibition of platelet functions and thrombosis through selective or nonselective inhibition of the platelet P2 receptors with increasing doses of NF449 [4,4',4'',4'''-(carbonylbis(imino-5,1,3-benzenetriylbis-(carbonylimino)))tetrakis-benzene-1,3-disulfonic acid octasodium salt].
Hechler B; Magnenat S; Zighetti ML; Kassack MU; Ullmann H; Cazenave JP; Evans R; Cattaneo M; Gachet C
J Pharmacol Exp Ther; 2005 Jul; 314(1):232-43. PubMed ID: 15792995
[TBL] [Abstract][Full Text] [Related]
2. The novel suramin analogue NF864 selectively blocks P2X1 receptors in human platelets with potency in the low nanomolar range.
Horner S; Menke K; Hildebrandt C; Kassack MU; Nickel P; Ullmann H; Mahaut-Smith MP; Lambrecht G
Naunyn Schmiedebergs Arch Pharmacol; 2005 Jul; 372(1):1-13. PubMed ID: 16158305
[TBL] [Abstract][Full Text] [Related]
3. NF449: a subnanomolar potency antagonist at recombinant rat P2X1 receptors.
Braun K; Rettinger J; Ganso M; Kassack M; Hildebrandt C; Ullmann H; Nickel P; Schmalzing G; Lambrecht G
Naunyn Schmiedebergs Arch Pharmacol; 2001 Sep; 364(3):285-90. PubMed ID: 11521173
[TBL] [Abstract][Full Text] [Related]
4. NF449, a novel picomolar potency antagonist at human P2X1 receptors.
Hülsmann M; Nickel P; Kassack M; Schmalzing G; Lambrecht G; Markwardt F
Eur J Pharmacol; 2003 May; 470(1-2):1-7. PubMed ID: 12787824
[TBL] [Abstract][Full Text] [Related]
5. The suramin analog 4,4',4'',4'''-(carbonylbis(imino-5,1,3-benzenetriylbis (carbonylimino)))tetra-kis-benzenesulfonic acid (NF110) potently blocks P2X3 receptors: subtype selectivity is determined by location of sulfonic acid groups.
Hausmann R; Rettinger J; Gerevich Z; Meis S; Kassack MU; Illes P; Lambrecht G; Schmalzing G
Mol Pharmacol; 2006 Jun; 69(6):2058-67. PubMed ID: 16551782
[TBL] [Abstract][Full Text] [Related]
6. Profiling at recombinant homomeric and heteromeric rat P2X receptors identifies the suramin analogue NF449 as a highly potent P2X1 receptor antagonist.
Rettinger J; Braun K; Hochmann H; Kassack MU; Ullmann H; Nickel P; Schmalzing G; Lambrecht G
Neuropharmacology; 2005 Mar; 48(3):461-8. PubMed ID: 15721178
[TBL] [Abstract][Full Text] [Related]
7. The ATP-gated P2X1 ion channel acts as a positive regulator of platelet responses to collagen.
Oury C; Toth-Zsamboki E; Thys C; Tytgat J; Vermylen J; Hoylaerts MF
Thromb Haemost; 2001 Nov; 86(5):1264-71. PubMed ID: 11816716
[TBL] [Abstract][Full Text] [Related]
8. Use of chimeras, point mutants, and molecular modeling to map the antagonist-binding site of 4,4',4″,4‴-(carbonylbis-(imino-5,1,3-benzenetriylbis(carbonylimino)))tetrakisbenzene-1,3-disulfonic acid (NF449) at P2X1 receptors for ATP.
Farmer LK; Schmid R; Evans RJ
J Biol Chem; 2015 Jan; 290(3):1559-69. PubMed ID: 25425641
[TBL] [Abstract][Full Text] [Related]
9. Effects of enhanced P2X1 receptor Ca2+ influx on functional responses in human platelets.
Rolf MG; Mahaut-Smith MP
Thromb Haemost; 2002 Sep; 88(3):495-502. PubMed ID: 12353081
[TBL] [Abstract][Full Text] [Related]
10. The platelet P2 receptors as molecular targets for old and new antiplatelet drugs.
Gachet C
Pharmacol Ther; 2005 Nov; 108(2):180-92. PubMed ID: 15955565
[TBL] [Abstract][Full Text] [Related]
11. On the mechanism of plasmin-induced platelet aggregation. Implications of the dual role of granule ADP.
Ishii-Watabe A; Uchida E; Mizuguchi H; Hayakawa T
Biochem Pharmacol; 2000 Jun; 59(11):1345-55. PubMed ID: 10751543
[TBL] [Abstract][Full Text] [Related]
12. Synergistic Inhibition of Both P2Y1 and P2Y12 Adenosine Diphosphate Receptors As Novel Approach to Rapidly Attenuate Platelet-Mediated Thrombosis.
Gremmel T; Yanachkov IB; Yanachkova MI; Wright GE; Wider J; Undyala VV; Michelson AD; Frelinger AL; Przyklenk K
Arterioscler Thromb Vasc Biol; 2016 Mar; 36(3):501-9. PubMed ID: 26743169
[TBL] [Abstract][Full Text] [Related]
13. Structure-activity relationships of analogues of NF449 confirm NF449 as the most potent and selective known P2X1 receptor antagonist.
Kassack MU; Braun K; Ganso M; Ullmann H; Nickel P; Böing B; Müller G; Lambrecht G
Eur J Med Chem; 2004 Apr; 39(4):345-57. PubMed ID: 15072843
[TBL] [Abstract][Full Text] [Related]
14. Ectodomain lysines and suramin block of P2X1 receptors.
Sim JA; Broomhead HE; North RA
J Biol Chem; 2008 Oct; 283(44):29841-6. PubMed ID: 18765669
[TBL] [Abstract][Full Text] [Related]
15. Benzoyl ATP is an antagonist of rat and human P2Y1 receptors and of platelet aggregation.
Vigne P; Hechler B; Gachet C; Breittmayer JP; Frelin C
Biochem Biophys Res Commun; 1999 Mar; 256(1):94-7. PubMed ID: 10066429
[TBL] [Abstract][Full Text] [Related]
16. No requirement of P2X1 purinoceptors for platelet aggregation.
Takano S; Kimura J; Matsuoka I; Ono T
Eur J Pharmacol; 1999 May; 372(3):305-9. PubMed ID: 10395026
[TBL] [Abstract][Full Text] [Related]
17. The ATP-gated P2X1 receptor plays a pivotal role in activation of aspirin-treated platelets by thrombin and epinephrine.
Grenegård M; Vretenbrant-Oberg K; Nylander M; Désilets S; Lindström EG; Larsson A; Ramström I; Ramström S; Lindahl TL
J Biol Chem; 2008 Jul; 283(27):18493-504. PubMed ID: 18480058
[TBL] [Abstract][Full Text] [Related]
18. Molecular basis for ADP-induced platelet activation. II. The P2Y1 receptor mediates ADP-induced intracellular calcium mobilization and shape change in platelets.
Jin J; Daniel JL; Kunapuli SP
J Biol Chem; 1998 Jan; 273(4):2030-4. PubMed ID: 9442040
[TBL] [Abstract][Full Text] [Related]
19. Protease-activated receptors 1 and 4 do not stimulate G(i) signaling pathways in the absence of secreted ADP and cause human platelet aggregation independently of G(i) signaling.
Kim S; Foster C; Lecchi A; Quinton TM; Prosser DM; Jin J; Cattaneo M; Kunapuli SP
Blood; 2002 May; 99(10):3629-36. PubMed ID: 11986217
[TBL] [Abstract][Full Text] [Related]
20. Modulation of neurotransmitter release by P2X and P2Y receptors in the rat spinal cord.
Heinrich A; Kittel A; Csölle C; Sylvester Vizi E; Sperlágh B
Neuropharmacology; 2008 Feb; 54(2):375-86. PubMed ID: 18063000
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
